Mounjaro vs Zepbound: What's the Difference? (Tirzepatide, Explained by a Queens MD)

Two names, one molecule

Once patients learn that Ozempic and Wegovy are the same drug, the next question is almost always: "Okay — then what about Mounjaro and Zepbound?" Same answer, different molecule.

I'm Dr. Keisha Bryant, a board-certified internal medicine physician in St Albans, Queens. Here's the plain-English version: Mounjaro and Zepbound are two brand names for the exact same active ingredient — tirzepatide. Both are made by the same manufacturer (Eli Lilly). The medicine injected into your body is identical. What differs is the FDA-approved use and the box it comes in — not the drug.

So why two names? For the same reason as Ozempic and Wegovy: the FDA approves a medication for a specific indication (the condition it's allowed to be marketed for), and the company brands the same molecule differently for each approved use.

The actual differences, side by side

That's the whole list. Same drug, same maker, same weekly injection, same dose range, same mechanism. The one real difference is what it's approved to treat — diabetes (Mounjaro) versus weight management (Zepbound).

What makes tirzepatide different from semaglutide

This is where Mounjaro/Zepbound genuinely differs from Ozempic/Wegovy — and it's a molecule difference, not just a brand one.

• Semaglutide (Ozempic/Wegovy) works on one gut hormone pathway: GLP-1.
• Tirzepatide (Mounjaro/Zepbound) works on two: GLP-1 and GIP. That's why it's called a dual agonist.

In plain terms, tirzepatide pulls two levers instead of one to reduce appetite and "food noise" and improve how your body handles blood sugar. In head-to-head clinical trials, that dual action tended to produce greater average weight loss than semaglutide — which is exactly why so many patients ask about it.

The simplest way to hold it in your head: Ozempic/Wegovy = semaglutide (one pathway). Mounjaro/Zepbound = tirzepatide (two pathways).

Why the FDA approvals differ

Same story as Ozempic and Wegovy:

• Mounjaro was FDA-approved first, for type 2 diabetes — to lower blood sugar in adults with diabetes. Patients on it also lost significant weight.
• Zepbound is the same tirzepatide molecule that Eli Lilly then got FDA-approved specifically for chronic weight management — for adults with obesity (BMI 30+) or who are overweight (BMI 27+) with a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea.

So "Mounjaro for weight loss" means a diabetes-labeled drug used off-label for weight; Zepbound is the version the FDA reviewed and approved for weight management. The medicine inside is tirzepatide either way.

What the weight-loss numbers actually look like

In the SURMOUNT clinical-trial program, adults on tirzepatide for weight management lost, on average, roughly 15–20% of body weight over about 72 weeks at the higher doses — among the largest averages seen for a weight-management medication to date. Individual results vary. These are clinical-trial averages, not a promise of what any one person will lose, and they were achieved with dose titration, follow-up, and lifestyle support — not the medication alone.

Does the difference matter for you?

Sometimes yes, sometimes no. What actually drives results:

• The dose you reach and tolerate. Both semaglutide and tirzepatide work by curbing appetite. The gains come from titrating up slowly to a dose your body handles well.
• Supervision and follow-up. A medication checked monthly by a physician — with labs and dose adjustments — beats a fixed prescription nobody is watching.
• The plan around it. Protein, strength training, and sleep protect your muscle and make the loss last.

Which molecule is right for you is a medical decision — based on your history, how you tolerate the medication, your goals, and cost. That's what the consult is for.

What we actually use: a cash-pay Tirzepatide program

At Dr. Bryant Medical, our medical weight-loss program offers Tirzepatide — the same active ingredient as Mounjaro and Zepbound — at $250/mo, all-inclusive. That covers the medication, a monthly MD check-in, dose titration, labs, unlimited messaging, and a nutrition plan.

Every patient is supervised by Dr. Keisha Bryant, MD — a board-certified physician. Whether a given patient's tirzepatide is a brand product or a compounded preparation depends on eligibility, availability, and your plan, and is decided with the MD at your consult — never a one-size-fits-all default. This isn't a fixed prescription you fill and forget.

Prefer the other molecule? We also offer Semaglutide — the same active ingredient as Ozempic/Wegovy — at $199/mo, all-inclusive. We compare the two directly in our Semaglutide vs Tirzepatide guide.

How we keep side effects manageable

The common side effects of tirzepatide are nausea, diarrhea, indigestion, and constipation — usually showing up during dose increases and typically easing within about a week. To keep them tolerable, Dr. Bryant titrates the dose gradually rather than jumping you to a high dose. Most people who go slowly tolerate it well.

Talk to us first if

Tirzepatide isn't right for everyone. Please tell us — and talk to us before starting — if any of these apply to you:

• You are pregnant or breastfeeding, or planning pregnancy.
• You have a personal or family history of medullary thyroid cancer, or MEN2 (multiple endocrine neoplasia type 2).
• You have a history of pancreatitis.
• You take medications that may interact with a GLP-1/GIP medicine, including insulin or other diabetes medicines. Tirzepatide can also reduce how well oral birth control is absorbed for a period after starting or increasing the dose — we'll talk through a backup plan if that applies to you.

These are exactly the things a physician screens for — and exactly what a telehealth site that never sees your history can't do safely.

Who qualifies?

Tirzepatide for weight management is generally appropriate for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea. That said, BMI is a screening tool, not a diagnosis — your final eligibility is decided by the MD at your free 15-minute consult, based on your history, labs, and goals.

The bottom line

If you're choosing between "Mounjaro and Zepbound," you're choosing between two brand names for one molecule — tirzepatide. The bigger, real choice is tirzepatide versus semaglutide — a two-pathway medicine versus a one-pathway one — and even that is less about the label than about the dose you reach, the supervision around it, and the plan you build.

We're at 205-15 Hollis Avenue, St Albans, NY 11412, phone +1 (929) 547-9616, open Mon–Sat 9–5. If you're in Queens and want a real plan built around your labs and your life, book a free 15-minute consult and we'll figure out together whether tirzepatide or semaglutide is right for you.

Note: This article is educational and not medical advice. Medications and weight-loss plans are individualized and prescribed only within a physician-patient relationship. Figures are clinical-trial averages; they are not a guarantee of individual results. Mounjaro and Zepbound are registered trademarks of Eli Lilly; this practice is not affiliated with or endorsed by the manufacturer.